LUPIN, France — — LUPINO, Italy — — Shares of LUPINE Pharmaceuticals, Inc. plunged after it reported a $3.3 billion loss for the year ended Feb. 15, raising the stock price to as much as 40 euros per share, according to data compiled by Bloomberg.LUPINE said it earned $3 billion in revenue and lost $3 million on revenue of $6.7 billion.
Lupine shares have risen 15% since Jan. 27, when it reported the loss and was down $1.80 to about 3 euros at 11:08 a.m. in Paris.
Shares of the U.S.-based drugmaker are down more than 11% since Nov. 30, the day the company announced the loss.
The shares of LAMPERE Pharmaceuticals fell more than 4% after it said its results for the second quarter of 2017 would be disappointing due to higher drug costs and increased competition.
Shares have declined more than 16% since Oct. 2, when the company reported a loss of $2.5 billion.
The U.K.-based company reported an operating loss of about $1 billion in the second-quarter, and is under pressure to cut spending in a bid to compete with big pharma’s $100 billion drug industry.LAMPERE shares fell nearly 3% to 1.3 euros.